{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:18:22Z","timestamp":1786979902699,"version":"build-2736575974"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T00:00:00Z","timestamp":1713312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T00:00:00Z","timestamp":1713312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872484"],"award-info":[{"award-number":["81872484"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>As one of the scheduled immunization vaccines worldwide, virtually all individuals have been vaccinated with BCG vaccine. In order to verify the hypothesis that delivering BCG high-affinity peptides to tumor areas could activate the existing BCG memory T cells to attack tumor, we firstly predicted the HLA-A*0201 high-affinity peptides of BCG Ag85A protein (KLIANNTRV, GLPVEYLQV), and then, A375 melanoma cells and HLA-A*0201 PBMCs (from PPD-positive adults) were added to co-incubated with the predicted peptides in vitro. We found that the predicted BCG high-affinity peptides could be directly loaded onto the surface of tumor cells, enhancing the tumor-killing efficacy of PBMCs from PPD-positive volunteer. Then, we constructed PPD-positive mice model bearing B16F10 subcutaneous tumors and found that intratumor injection of BCG Ag85A high-affinity peptides (SGGANSPAL, YHPQQFVYAGAMSGLLD) enhanced the anti-tumor efficacy in PPD-positive melanoma mice. Along with the better anti-tumor efficacy, the expression of PDL1 on tumor cell surface was also increased, and stronger antitumor effects occurred when further combined with anti-PD1 antibody. For microenvironment analysis, the proportion of effector memory T cells was increased and the better treatment efficacy may be attributed to the elevated effector memory CD4\u2009+\u2009T cells within the tumor. In conclusion, using the existing immune response of BCG vaccine by delivering high-affinity peptides of BCG to tumor area is a safe and promising therapy for cancer.<\/jats:p>","DOI":"10.1007\/s00262-024-03693-7","type":"journal-article","created":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T09:02:03Z","timestamp":1713344523000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Intratumor injection of BCG Ag85A high-affinity peptides enhanced anti-tumor efficacy in PPD-positive melanoma"],"prefix":"10.1007","volume":"73","author":[{"given":"Lanqun","family":"Qin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yirong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueling","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyun","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,17]]},"reference":[{"key":"3693_CR1","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.tube.2005.08.020","volume":"86","author":"H Aggerbeck","year":"2006","unstructured":"Aggerbeck H, Madsen SM (2006) Safety of ESAT-6. Tuberculosis (Edinb) 86:363\u2013373","journal-title":"Tuberculosis (Edinb)"},{"key":"3693_CR2","doi-asserted-by":"publisher","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","volume":"30","author":"NM Anderson","year":"2020","unstructured":"Anderson NM, Simon MC (2020) The tumor microenvironment. Curr Biol 30:R921\u2013R925","journal-title":"Curr Biol"},{"key":"3693_CR3","doi-asserted-by":"publisher","first-page":"18627","DOI":"10.1073\/pnas.2004421117","volume":"117","author":"AC Antonelli","year":"2020","unstructured":"Antonelli AC, Binyamin A, Hohl TM, Glickman MS, Redelman-Sidi G (2020) Bacterial immunotherapy for cancer induces CD4-dependent tumor-specific immunity through tumor-intrinsic interferon-gamma signaling. Proc Natl Acad Sci U S A 117:18627\u201318637","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3693_CR4","doi-asserted-by":"publisher","first-page":"7903","DOI":"10.1007\/s00253-019-10057-0","volume":"103","author":"MLR Benitez","year":"2019","unstructured":"Benitez MLR, Bender CB, Oliveira TL, Schachtschneider KM, Collares T, Seixas FK (2019) Mycobacterium bovis BCG in metastatic melanoma therapy. Appl Microbiol Biotechnol 103:7903\u20137916","journal-title":"Appl Microbiol Biotechnol"},{"key":"3693_CR5","doi-asserted-by":"publisher","first-page":"E1754","DOI":"10.1073\/pnas.1500973112","volume":"112","author":"D Chowell","year":"2015","unstructured":"Chowell D, Krishna S, Becker PD, Cocita C, Shu J, Tan X et al (2015) TCR contact residue hydrophobicity is a hallmark of immunogenic CD8+ T cell epitopes. Proc Natl Acad Sci U S A 112:E1754-1762","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3693_CR6","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41586-019-1817-8","volume":"577","author":"PA Darrah","year":"2020","unstructured":"Darrah PA, Zeppa JJ, Maiello P, Hackney JA, Wadsworth MH 2nd, Hughes TK et al (2020) Prevention of tuberculosis in macaques after intravenous BCG immunization. Nature 577:95\u2013102","journal-title":"Nature"},{"key":"3693_CR7","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1016\/j.vaccine.2011.02.010","volume":"29","author":"SC Derrick","year":"2011","unstructured":"Derrick SC, Yabe IM, Yang A, Morris SL (2011) Vaccine-induced anti-tuberculosis protective immunity in mice correlates with the magnitude and quality of multifunctional CD4 T cells. Vaccine 29:2902\u20132909","journal-title":"Vaccine"},{"key":"3693_CR8","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni1102-991","volume":"3","author":"GP Dunn","year":"2002","unstructured":"Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991\u2013998","journal-title":"Nat Immunol"},{"key":"3693_CR9","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.4049\/jimmunol.1601064","volume":"198","author":"DA Erkes","year":"2017","unstructured":"Erkes DA, Smith CJ, Wilski NA, Caldeira-Dantas S, Mohgbeli T, Snyder CM (2017) Virus-Specific CD8(+) T Cells Infiltrate Melanoma Lesions and Retain Function Independently of PD-1 Expression. J Immunol 198:2979\u20132988","journal-title":"J Immunol"},{"key":"3693_CR10","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/imr.12965","volume":"301","author":"M Foster","year":"2021","unstructured":"Foster M, Hill PC, Setiabudiawan TP, Koeken V, Alisjahbana B, van Crevel R (2021) BCG-induced protection against mycobacterium tuberculosis infection: evidence, mechanisms, and implications for next-generation vaccines. Immunol Rev 301:122\u2013144","journal-title":"Immunol Rev"},{"key":"3693_CR11","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","volume":"19","author":"A Garcia-Diaz","year":"2017","unstructured":"Garcia-Diaz A, Shin DS, Moreno BH, Saco J, Escuin-Ordinas H, Rodriguez GA et al (2017) Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep 19:1189\u20131201","journal-title":"Cell Rep"},{"key":"3693_CR12","doi-asserted-by":"publisher","first-page":"16612","DOI":"10.3390\/ijms242316612","volume":"24","author":"X Guo","year":"2023","unstructured":"Guo X, Du W, Li J, Dong J, Shen X, Su C et al (2023A) Comparative study on the mechanism of delayed-type hypersensitivity mediated by the recombinant mycobacterium tuberculosis fusion protein ESAT6-CFP10 and purified protein derivative. Int J Mol Sci 24:16612","journal-title":"Int J Mol Sci"},{"key":"3693_CR13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13045-019-0812-8","volume":"12","author":"Q He","year":"2019","unstructured":"He Q, Jiang X, Zhou X, Weng J (2019) Targeting cancers through TCR-peptide\/MHC interactions. J Hematol Oncol 12:139","journal-title":"J Hematol Oncol"},{"key":"3693_CR14","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1159\/000246222","volume":"193","author":"BM Henz","year":"1996","unstructured":"Henz BM, Macher E, Brocker EB, Suciu S, Steerenberg PA, Jung E et al (1996) Prognostic value of tuberculin and BCG immunoreactivity in stage I high-risk malignant melanoma (EORTC protocol 18781). Dermatology 193:105\u2013109","journal-title":"Dermatology"},{"key":"3693_CR15","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.jconrel.2013.02.002","volume":"167","author":"K Ichikawa","year":"2013","unstructured":"Ichikawa K, Asai T, Shimizu K, Yonezawa S, Urakami T, Miyauchi H et al (2013) Suppression of immune response by antigen-modified liposomes encapsulating model agents: a novel strategy for the treatment of allergy. J Control Release 167:284\u2013289","journal-title":"J Control Release"},{"key":"3693_CR16","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1158\/2326-6066.CIR-21-0285","volume":"9","author":"N Ji","year":"2021","unstructured":"Ji N, Mukherjee N, Shu ZJ, Reyes RM, Meeks JJ, McConkey DJ et al (2021) gammadelta T Cells support antigen-specific alphabeta T cell-mediated antitumor responses during bcg treatment for bladder cancer. Cancer Immunol Res 9:1491\u20131503","journal-title":"Cancer Immunol Res"},{"key":"3693_CR17","doi-asserted-by":"publisher","first-page":"e003960","DOI":"10.1136\/jitc-2021-003960","volume":"10","author":"X Jiang","year":"2022","unstructured":"Jiang X, Wang J, Zheng X, Liu Z, Zhang X, Li Y et al (2022) Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy. J Immunother Cancer 10:e003960","journal-title":"J Immunother Cancer"},{"key":"3693_CR18","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/s41586-021-03368-8","volume":"592","author":"S Kalaora","year":"2021","unstructured":"Kalaora S, Nagler A, Nejman D, Alon M, Barbolin C, Barnea E et al (2021) Identification of bacteria-derived HLA-bound peptides in melanoma. Nature 592:138\u2013143","journal-title":"Nature"},{"key":"3693_CR19","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.micpath.2017.08.040","volume":"112","author":"M Karbalaei Zadeh Babaki","year":"2017","unstructured":"Karbalaei Zadeh Babaki M, Soleimanpour S, Rezaee SA (2017) Antigen 85 complex as a powerful Mycobacterium tuberculosis immunogene: biology, immune-pathogenicity, applications in diagnosis, and vaccine design. Microb Pathog 112:20\u201329","journal-title":"Microb Pathog"},{"key":"3693_CR20","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nmat4822","volume":"16","author":"R Kuai","year":"2017","unstructured":"Kuai R, Ochyl LJ, Bahjat KS, Schwendeman A, Moon JJ (2017) Designer vaccine nanodiscs for personalized cancer immunotherapy. Nat Mater 16:489\u2013496","journal-title":"Nat Mater"},{"key":"3693_CR21","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/apm.13011","volume":"128","author":"ES Larsen","year":"2020","unstructured":"Larsen ES, Joensen UN, Poulsen AM, Goletti D, Johansen IS (2020) Bacillus Calmette-Guerin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections. APMIS 128:92\u2013103","journal-title":"APMIS"},{"key":"3693_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-017-0008-6","author":"DA Lewinsohn","year":"2017","unstructured":"Lewinsohn DA, Swarbrick GM, Park B, Cansler ME, Null MD, Toren KG et al (2017) Comprehensive definition of human immunodominant CD8 antigens in tuberculosis. NPJ Vaccines. https:\/\/doi.org\/10.1038\/s41541-017-0008-6","journal-title":"NPJ Vaccines"},{"key":"3693_CR23","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/1078-0432.CCR-16-0224","volume":"22","author":"M Mandai","year":"2016","unstructured":"Mandai M, Hamanishi J, Abiko K, Matsumura N, Baba T, Konishi I (2016) Dual faces of IFNgamma in cancer progression: a role of PD-L1 induction in the determination of pro- and antitumor immunity. Clin Cancer Res 22:2329\u20132334","journal-title":"Clin Cancer Res"},{"key":"3693_CR24","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S0021-9258(17)49904-2","volume":"295","author":"RA Mariuzza","year":"2020","unstructured":"Mariuzza RA, Agnihotri P, Orban J (2020) The structural basis of T-cell receptor (TCR) activation: an enduring enigma. J Biol Chem 295:914\u2013925","journal-title":"J Biol Chem"},{"key":"3693_CR25","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s43018-022-00335-8","volume":"3","author":"SL Meier","year":"2022","unstructured":"Meier SL, Satpathy AT, Wells DK (2022) Bystander T cells in cancer immunology and therapy. Nat Cancer 3:143\u2013155","journal-title":"Nat Cancer"},{"key":"3693_CR26","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/s41587-019-0404-8","volume":"38","author":"DG Millar","year":"2020","unstructured":"Millar DG, Ramjiawan RR, Kawaguchi K, Gupta N, Chen J, Zhang S et al (2020) Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy. Nat Biotechnol 38:420\u2013425","journal-title":"Nat Biotechnol"},{"key":"3693_CR27","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1086\/422394","volume":"190","author":"HJ Mollenkopf","year":"2004","unstructured":"Mollenkopf HJ, Kursar M, Kaufmann SH (2004) Immune response to postprimary tuberculosis in mice: mycobacterium tuberculosis and miycobacterium bovis bacille Calmette-Guerin induce equal protection. J Infect Dis 190:588\u2013597","journal-title":"J Infect Dis"},{"key":"3693_CR28","doi-asserted-by":"publisher","first-page":"6090","DOI":"10.1038\/s41467-023-41768-8","volume":"14","author":"E Moreo","year":"2023","unstructured":"Moreo E, Jarit-Cabanillas A, Robles-Vera I, Uranga S, Guerrero C, Gomez AB et al (2023) Intravenous administration of BCG in mice promotes natural killer and T cell-mediated antitumor immunity in the lung. Nat Commun 14:6090","journal-title":"Nat Commun"},{"key":"3693_CR29","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1097\/00000658-197410000-00029","volume":"180","author":"DL Morton","year":"1974","unstructured":"Morton DL, Eilber FR, Holmes EC, Hunt JS, Ketcham AS, Silverstein MJ et al (1974) BCG immunotherapy of malignant melanoma: summary of a seven-year experience. Ann Surg 180:635\u2013643","journal-title":"Ann Surg"},{"key":"3693_CR30","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1172\/JCI97642","volume":"129","author":"D Muraoka","year":"2019","unstructured":"Muraoka D, Seo N, Hayashi T, Tahara Y, Fujii K, Tawara I et al (2019) Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance. J Clin Invest 129:1278\u20131294","journal-title":"J Clin Invest"},{"key":"3693_CR31","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1126\/science.aay9189","volume":"368","author":"D Nejman","year":"2020","unstructured":"Nejman D, Livyatan I, Fuks G, Gavert N, Zwang Y, Geller LT et al (2020) The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science 368:973\u2013980","journal-title":"Science"},{"key":"3693_CR32","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00262-012-1366-6","volume":"62","author":"D Nobuoka","year":"2013","unstructured":"Nobuoka D, Yoshikawa T, Takahashi M, Iwama T, Horie K, Shimomura M et al (2013) Intratumoral peptide injection enhances tumor cell antigenicity recognized by cytotoxic T lymphocytes: a potential option for improvement in antigen-specific cancer immunotherapy. Cancer Immunol Immunother 62:639\u2013652","journal-title":"Cancer Immunol Immunother"},{"key":"3693_CR33","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/s41577-022-00707-2","volume":"22","author":"N Pishesha","year":"2022","unstructured":"Pishesha N, Harmand TJ, Ploegh HL (2022) A guide to antigen processing and presentation. Nat Rev Immunol 22:751\u2013764","journal-title":"Nat Rev Immunol"},{"key":"3693_CR34","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41467-019-08534-1","volume":"10","author":"PC Rosato","year":"2019","unstructured":"Rosato PC, Wijeyesinghe S, Stolley JM, Nelson CE, Davis RL, Manlove LS et al (2019) Virus-specific memory T cells populate tumors and can be repurposed for tumor immunotherapy. Nat Commun 10:567","journal-title":"Nat Commun"},{"key":"3693_CR35","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3892\/ijo.2014.2737","volume":"46","author":"Y Sawada","year":"2015","unstructured":"Sawada Y, Yoshikawa T, Shimomura M, Iwama T, Endo I, Nakatsura T (2015) Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes. Int J Oncol 46:28\u201336","journal-title":"Int J Oncol"},{"key":"3693_CR36","doi-asserted-by":"publisher","first-page":"5648","DOI":"10.3390\/cancers14225648","volume":"14","author":"M Sheinin","year":"2022","unstructured":"Sheinin M, Jeong B, Paidi RK, Pahan K (2022) Regression of lung cancer in mice by intranasal administration of SARS-CoV-2 spike S1. Cancers (Basel) 14:5648","journal-title":"Cancers (Basel)"},{"key":"3693_CR37","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s41586-018-0130-2","volume":"557","author":"Y Simoni","year":"2018","unstructured":"Simoni Y, Becht E, Fehlings M, Loh CY, Koo SL, Teng KWW et al (2018) Bystander CD8(+) T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature 557:575\u2013579","journal-title":"Nature"},{"key":"3693_CR38","doi-asserted-by":"publisher","first-page":"7088","DOI":"10.4049\/jimmunol.165.12.7088","volume":"165","author":"SM Smith","year":"2000","unstructured":"Smith SM, Brookes R, Klein MR, Malin AS, Lukey PT, King AS et al (2000) Human CD8+ CTL specific for the mycobacterial major secreted antigen 85A. J Immunol 165:7088\u20137095","journal-title":"J Immunol"},{"key":"3693_CR39","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1056\/NEJM197310182891603","volume":"289","author":"FC Sparks","year":"1973","unstructured":"Sparks FC, Silverstein MJ, Hunt JS, Haskell CM, Pilch YH, Morton DL (1973) Complications of BCG immunotherapy in patients with cancer. N Engl J Med 289:827\u2013830","journal-title":"N Engl J Med"},{"key":"3693_CR40","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/978-3-030-37184-5_2","volume":"1234","author":"M Truffi","year":"2020","unstructured":"Truffi M, Sorrentino L, Corsi F (2020) Fibroblasts in the tumor microenvironment. Adv Exp Med Biol 1234:15\u201329","journal-title":"Adv Exp Med Biol"},{"key":"3693_CR41","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1084\/jem.157.3.1040","volume":"157","author":"C Uyttenhove","year":"1983","unstructured":"Uyttenhove C, Maryanski J, Boon T (1983) Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J Exp Med 157:1040\u20131052","journal-title":"J Exp Med"},{"key":"3693_CR42","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.trecan.2017.07.007","volume":"3","author":"N Vigneron","year":"2017","unstructured":"Vigneron N, Abi Habib J, Van den Eynde BJ (2017) Learning from the proteasome how to fine-tune cancer immunotherapy. Trends Cancer 3:726\u2013741","journal-title":"Trends Cancer"},{"key":"3693_CR43","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41392-023-01646-7","volume":"8","author":"Y Wang","year":"2023","unstructured":"Wang Y, Han J, Wang D, Cai M, Xu Y, Hu Y et al (2023) Anti-PD-1 antibody armored gammadelta T cells enhance anti-tumor efficacy in ovarian cancer. Signal Transduct Target Ther 8:399","journal-title":"Signal Transduct Target Ther"},{"key":"3693_CR44","first-page":"3851","volume":"50","author":"PL Ward","year":"1990","unstructured":"Ward PL, Koeppen HK, Hurteau T, Rowley DA, Schreiber H (1990) Major histocompatibility complex class I and unique antigen expression by murine tumors that escaped from CD8+ T-cell-dependent surveillance. Cancer Res 50:3851\u20133858","journal-title":"Cancer Res"},{"key":"3693_CR45","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3389\/fvets.2017.00107","volume":"4","author":"Z Xu","year":"2017","unstructured":"Xu Z, Hu T, Xia A, Li X, Liu Z, Min J et al (2017) Generation of monoclonal antibodies against Ag85A antigen of mycobacterium tuberculosis and application in a competitive ELISA for serodiagnosis of bovine tuberculosis. Front Vet Sci 4:107","journal-title":"Front Vet Sci"},{"key":"3693_CR46","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1158\/0008-5472.CAN-21-2200","volume":"82","author":"S Zhang","year":"2022","unstructured":"Zhang S, Yan C, Millar DG, Yang Q, Heather JM, Langenbucher A et al (2022) Antibody-peptide epitope conjugates for personalized cancer therapy. Cancer Res 82:773\u2013784","journal-title":"Cancer Res"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03693-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-024-03693-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03693-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T09:02:24Z","timestamp":1715418144000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-024-03693-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,17]]},"references-count":46,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["3693"],"URL":"https:\/\/doi.org\/10.1007\/s00262-024-03693-7","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,17]]},"assertion":[{"value":"16 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author(s) declared no potential conflicts of interest concerning the research, authorship, and\/or publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The blood collection procedure was developed in accordance with the guidelines that have been approved by the Ethics Committee of Nanjing Drum Tower Hospital. All donors gave informed consent for their samples to be used in scientific studies. All animal procedures were carried out in compliance with guidelines set by the Animal Care Committee of Drum Tower Hospital (No.2020AE01080).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"103"}}